article thumbnail

mRNA: A New Era in Biopharmaceutical Contract Manufacturing Market

Roots Analysis

The success of COVID-19 vaccines paved the path for mRNA-based drug products. Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the contract manufacturing service providers to cater to the urgent global demand.

article thumbnail

Yale-NBA Partnership Results in FDA Approval for COVID-19 SalivaDirect Test

XTalks

An important feature of the test that contributes to its reduced cost is the fact that sample processing does not require a separate nucleic acid (RNA) extraction step. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Transforming Biomanufacturing: Potential of Cell Free Systems

Roots Analysis

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. Used in the COVID-19 vaccines, LNPs have shown a promising track record of protecting the mRNA cargo from degradation. Does it degrade?

Bioassay 130
article thumbnail

mRNA Synthesis: ManufacturingProcess of Modern Revolutionary Molecule

Roots Analysis

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.

article thumbnail

Tackling the Challenges of Limited Resources During a Pandemic

The Pharma Data

The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. delays where reagents are in. Biogazelle, an innovative bioanalytical services company offering RNA and. effective SARS-CoV-2 vaccine continues to attract.

Reagent 52
article thumbnail

Casting aside CRISPR scissors and making a point with base editors

pharmaphorum

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.